{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:52:46Z","timestamp":1787017966120,"version":"build-2736575974"},"reference-count":68,"publisher":"Georg Thieme Verlag KG","issue":"S 02","funder":[{"name":"Bayer Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Atrial fibrillation (AF) is a major healthcare concern, being associated with an estimated five-fold risk of ischaemic stroke. In patients with AF, anticoagulants reduce stroke risk to a greater extent than acetylsalicylic acid (ASA) or dual antiplatelet therapy (DAPT) with ASA plus clopidogrel. Non-vitamin K antagonist oral anticoagulants (NOACs) are now a widely-accepted therapeutic option for stroke prevention in non-valvular AF (NVAF). There are particular patient types with NVAF for whom treatment challenges remain, owing to sparse clinical data, their high-risk nature or a need to harmonise anticoagulant and antiplatelet regimens if co-administered. This article focuses on three randomised controlled trials (RCTs) that are investigating the utility of rivaroxaban, a direct, oral, factor Xa inhibitor, in additional areas of stroke prevention where data for anticoagulants are lacking: oPenlabel, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment (PIONEER AF-PCI); New Approach riVaroxoban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS); and Global study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement to Optimize clinical outcomes (GALILEO). Data from these studies present collaborative efforts to build upon existing registrational Phase III data for rivaroxaban, driving the need for effective and safe treatment of a wider range of patients for stroke prevention.<\/jats:p>","DOI":"10.1160\/th16-06-0487","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T04:00:54Z","timestamp":1473825654000},"page":"S33-S40","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials"],"prefix":"10.1160","volume":"116","author":[{"given":"Melanie","family":"Hemmrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Thomitzek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"10.1160\/TH16-06-0487-1","unstructured":"World Health Organization. The Atlas of Heart Disease and Stroke. World Health Organization. Available at: http:\/\/www.who.int\/cardiovascular_diseases\/resources\/atlas\/en\/. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0487-2","unstructured":"European Heart Network and European Society of Cardiology. 2012 European Cardiovascular Disease Statistics. European Society of Cardiology. Available at: http:\/\/www.escardio.org\/The-ESC\/Initiatives\/EuroHeart\/2012-European-Cardiovascular-Disease-Statistics. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0487-3","first-page":"257","volume":"27","author":"Wyndham","year":"2000","journal-title":"Tex Heart Inst J"},{"key":"10.1160\/TH16-06-0487-4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00713-4"},{"key":"10.1160\/TH16-06-0487-5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595140"},{"key":"10.1160\/TH16-06-0487-6","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"10.1160\/TH16-06-0487-7","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1765"},{"key":"10.1160\/TH16-06-0487-8","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"10.1160\/TH16-06-0487-9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2441"},{"key":"10.1160\/TH16-06-0487-10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"10.1160\/TH16-06-0487-11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"10.1160\/TH16-06-0487-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.03.008"},{"key":"10.1160\/TH16-06-0487-13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.025"},{"key":"10.1160\/TH16-06-0487-14","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-9022-7"},{"key":"10.1160\/TH16-06-0487-15","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.516344"},{"key":"10.1160\/TH16-06-0487-16","unstructured":"Bayer Pharma AG. Xarelto Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf"},{"key":"10.1160\/TH16-06-0487-17","unstructured":"Boehringer Ingelheim. Pradaxa Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0487-18","unstructured":"Bristol-Myers Squibb. Eliquis Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0487-19","unstructured":"Daiichi Sankyo. Lixiana Summary of Product Characteristics. European Medicines Agency. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0487-20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10.1160\/TH16-06-0487-21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"10.1160\/TH16-06-0487-22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.08.001"},{"key":"10.1160\/TH16-06-0487-23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"10.1160\/TH16-06-0487-24","doi-asserted-by":"publisher","DOI":"10.1177\/0003319711427391"},{"key":"10.1160\/TH16-06-0487-25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn579"},{"key":"10.1160\/TH16-06-0487-26","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.06.001"},{"key":"10.1160\/TH16-06-0487-27","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;"},{"key":"10.1160\/TH16-06-0487-28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"10.1160\/TH16-06-0487-29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278"},{"key":"10.1160\/TH16-06-0487-30","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0262"},{"key":"10.1160\/TH16-06-0487-31","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-08-0580"},{"key":"10.1160\/TH16-06-0487-32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"10.1160\/TH16-06-0487-33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.1160\/TH16-06-0487-34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.041"},{"key":"10.1160\/TH16-06-0487-35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.12.006"},{"key":"10.1160\/TH16-06-0487-36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"10.1160\/TH16-06-0487-37","unstructured":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI). https:\/\/ClinicalTrials.gov\/show\/NCT02164864"},{"key":"10.1160\/TH16-06-0487-38","unstructured":"A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart. https:\/\/ClinicalTrials.gov\/show\/NCT02415400"},{"key":"10.1160\/TH16-06-0487-39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.011147"},{"key":"10.1160\/TH16-06-0487-40","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"10.1160\/TH16-06-0487-41","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.630384"},{"key":"10.1160\/TH16-06-0487-42","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.596189"},{"key":"10.1160\/TH16-06-0487-43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805002"},{"key":"10.1160\/TH16-06-0487-44","unstructured":"Clinical Neurology News Digital Network. Think ESUS, not cryptogenic stroke. Clinical Neurology News Network. Available at: http:\/\/www.clinicalneurologynews.com\/specialty-focus\/cerebrovascular-critical-care\/single-article-page\/think-esus-not-cryptogenic-stroke\/0866c8d965227e3fab381e2277927d10.html. Accessed May 18, 2016"},{"key":"10.1160\/TH16-06-0487-45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"10.1160\/TH16-06-0487-46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"10.1160\/TH16-06-0487-47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"10.1160\/TH16-06-0487-48","unstructured":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS). https:\/\/ClinicalTrials.gov\/show\/NCT02313909"},{"key":"10.1160\/TH16-06-0487-49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"10.1160\/TH16-06-0487-50","doi-asserted-by":"publisher","DOI":"10.2165\/11595320-000000000-00000"},{"key":"10.1160\/TH16-06-0487-51","unstructured":"Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS). https:\/\/ClinicalTrials.gov\/show\/NCT02239120"},{"key":"10.1160\/TH16-06-0487-52","unstructured":"Apixaban for Treatment of Embolic Stroke of Undetermined Source. https:\/\/ClinicalTrials.gov\/show\/NCT02427126"},{"key":"10.1160\/TH16-06-0487-53","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV8I1A20"},{"key":"10.1160\/TH16-06-0487-54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008232"},{"key":"10.1160\/TH16-06-0487-55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.556"},{"key":"10.1160\/TH16-06-0487-56","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY15M09_11"},{"key":"10.1160\/TH16-06-0487-57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.05.017"},{"key":"10.1160\/TH16-06-0487-58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1514616"},{"key":"10.1160\/TH16-06-0487-59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.149492"},{"key":"10.1160\/TH16-06-0487-60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.022"},{"key":"10.1160\/TH16-06-0487-61","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-10-0821"},{"key":"10.1160\/TH16-06-0487-62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.08.052"},{"key":"10.1160\/TH16-06-0487-63","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.11.026"},{"key":"10.1160\/TH16-06-0487-64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2011.08.012"},{"key":"10.1160\/TH16-06-0487-65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509233"},{"key":"10.1160\/TH16-06-0487-66","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2007.12.014"},{"key":"10.1160\/TH16-06-0487-67","unstructured":"Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an Antiplatelet-based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes. https:\/\/ClinicalTrials.gov\/show\/NCT02556203"},{"key":"10.1160\/TH16-06-0487-68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2012.09.002"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH16-06-0487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T10:32:27Z","timestamp":1521541947000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH16-06-0487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":68,"journal-issue":{"issue":"S 02","published-online":{"date-parts":[[2017,12,15]]},"published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1160\/th16-06-0487","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}